1. Warlo, E. M. K. A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease / E. M. K. Warlo, H. Arnesen, I. Seljeflot // Thrombosis J. – 2019. – Vol. 17, N 1. – Art. 11. https://doi.org/10.1186/s12959-019-0197-5

2. The personalization of clopidogrel antiplatelet therapy: the role of integrative pharmacogenetics and pharmacometabolomics / A. M. Amin [et al.] // Cardiol. Res. Pract. – 2017. – Vol. 2017. – Art. ID 8062796. https://doi.org/10.1155/2017/8062796

3. Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy / M. Jarrar [et al.] // Mol. Biol. Rep. – 2016. – Vol. 43, N 6. – P. 473–484. https://doi.org/10.1007/s11033-016-3983-1

4. Purinergic receptor P2Y, G protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolism / R. Y. Zee [et al.] // Atherosclerosis. – 2008. – Vol. 197, N 2. – Р. 694–699. https://doi.org/10.1016/j.atherosclerosis.2007.07.001

5. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects / P. Fontana [et al.] // Circulation. – 2003. – Vol. 108, N 8. – P. 989–995. https://doi.org/10.1161/01.CIR.0000085073.69189.88

6. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease / S. Ziegler [et al.] // Stroke. – 2005. – Vol. 36, N 7. – P. 1394–1399. https://doi.org/10.1161/01.STR.0000169922.79281.a5

7. Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease / U. Cavallari [et al.] // BMC Med. Genet. – 2007. – Vol. 8, N 59. – Art. 59. https://doi.org/10.1186/1471-2350-8-59

8. Каражанова, Л. К. Молекулярно-генетические основы диагностики и лечения ишемической болезни сердца (обзор литературы) / Л. К. Каражанова, Ш. Т. Жукушева, А. А. Чиныбаева // Наука и здравоохранение. – 2014. – № 3. – С. 4–11.

9. Identification of ITGA2B and ITGB3 single-nucleotide polymorphisms and their influences on the platelet function / Q. Xiang [et al.] // Biomed. Res. Int. – 2016. – Vol. 2016. – Art. ID 5675084. https://doi.org/10.1155/2016/5675084

10. Evaluation of platelet reactivity during combined antiplatelet therapy in patients with stable coronary artery disease in relation to diabetes type 2 and the GPIIB/IIIA receptor gene polymorphism / M. Jastrzebska [et al.] // J. Physiol. Pharmacol. – 2019. – Vol. 70, N 2. – P. 175–185. https://doi.org/10.26402/jpp.2019.2.01

11. Calatzis, A. Multiplate platelet function analysis – application and interpretation / A. Calatzis, R. Loreth, M. Spannagl // Verum Diagnostica GmbH. – 2007. – P. 1–35.

12. Interethnic variation of CYP2C19 alleles, “predicted” phenotypes and “measured” metabolic phenotypes across world populations / I. Fricke-Galindo [et al.] // Pharmacogenomics J. – 2016. – Vol. 16, N 2. – P. 113–123. https://doi.org/10.1038/tpj.2015.70

13. Zhou, Y. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects / Y. Zhou, M. Ingelman-Sundberg V. M. Lauschke // Clin. Pharmacol. Ther. – 2017. – Vol. 102, N 4. – P. 688–700. https://doi.org/10.1002/cpt.690

14. Petrović, J. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe / J. Petrović, V. Pešić, V. M. Lauschke // Eur. J. Hum. Genet. – 2020. – Vol. 28, N 1. – P. 88–94. https://doi.org/10.1038/s41431-019-0480-8

15. Муслимова, Э. Ф. Молекулярно-генетические факторы развития осложнений после стентирования коронарных артерий у больных хронической ИБС : автореф. дис. … канд. мед. наук : 14.03.03 ; 14.01.05 / Э. Ф. Муслимова ; Сибир. гос. мед. ун-т. – Томск, 2016. – 21 с.

16. Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population / A. Polonikov [et al.] // Gene. – 2017. – Vol. 627. – P. 451–459. https://doi.org/10.1016/j.gene.2017.07.004

17. Возможные генетические предикторы развития сердечно-сосудистых осложнений после коронарного шунтирования / Ю. И. Гринштейн [и др.] // Кардиология. – 2018. – Т. 58, № 7. – С. 77–84.

18. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions / G. Rudez [et al.] // Circ. Cardiovasc. Genet. – 2009. – Vol. 2, N 5. – P. 515–521. https://doi.org/10.1161/CIRCGENETICS.109.861799

19. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease / Anselmi [et al.] // JACC: Cardiol. Intv. – 2013. – Vol. 6, N 11. – P. 1166–1175. https://doi.org/10.1016/j.jcin.2013.06.010

20. Association of polymorphisms of platelet receptors GPIa (807C>T), GPVI (13254T>C), and P2Y12 (34C>T and H1/H2 haplotype) with increased risk of periprocedural bleeding in patients undergoing coronary angiography/ percutaneous coronary intervention / M. Sionova [et al.] // Adv. Interv. Cardiol. – 2017. – Vol. 13, N 3. – P. 202–209. https://doi.org/10.5114/aic.2017.70187

21. Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects / J. H. Oestreich [et al.] // J. Thromb. Thrombolysis. – 2014. – Vol. 38, N 3. – P. 372–379. https://doi.org/10.1007/s11239-014-1058-5

22. Резистентность к клопидогрелу и полиморфизмы генов P2RY12 и GPIIIA у больных хронической ишемической болезнью сердца / Т. Ю. Реброва [и др.] // Клин. медицина. – 2013. – Т. 91, № 8. – С. 29–31.

23. Страмбовская, Н. Н. Агрегационная активность тромбоцитов у носителей генетического полиморфизма GPIA (С807Т), GPIIIA (Т1565С), GPIβα (С434Т), P2RY12 (Н1/Н2), SELP (G1087A) тромбоцитарных рецепторов / Н. Н. Страмбовская // Бюл. ВСНЦ СО РАМН. – 2013. – № 6 (94). – С. 65–70.

24. P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting / N. Zoheir [et al.] // Blood Coagul. Fibrinolysis. – 2013. – Vol. 24, N 5. – P. 525–531. https://doi.org/10.1097/MBC.0b013e32835e98bf

25. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease / D. J. Angiolillo [et al.] // Thromb. Res. – 2005. – Vol. 116, N 6. – P. 491–497. https://doi.org/10.1016/j.thromres.2005.03.001

26. Genetic determinants of response to clopidogrel and cardiovascular events / T. Simon [et al.] // N. Engl. J. Med. – 2009. – Vol. 360, N 4. – P. 363–375. https://doi.org/10.1056/NEJMoa0808227

27. Platelet glycoprotein IIb/IIIa polymorphism and coronary artery disease: implications for clinical practice / A. di Castelnuovo [et al.] // Am. J. Pharmacogenomics. – 2005. – Vol. 5, N 2. – P. 93–99. https://doi.org/10.2165/00129785-200505020-00002

28. Khatami, M. Common rs5918 (PlA1/A2) polymorphism in the ITGB3 gene and risk of coronary artery disease / M. Khatami, M. M. Heidari, S. Soheilyfar // Arch. Med. Sci. Atheroscler. Dis. – 2016. – Vol. 1. – P. e9–e15. https://doi.org/10.5114/amsad.2016.59587

29. Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: a prospective multicentre registry study / H. J. Joo [et al.] // Sci. Reports. – 2018. – Vol. 8, N 1. – Art. 1229. https://doi.org/10.1038/s41598-017-18134-y

30. Influence of CYP2C19 genotype on antiplatelet treatment outcomes after percutaneous coronary intervention in patients with coronary heart disease / D. Yu [et al.] // Exp. Ther. Med. – 2020 – Vol. 19, N 5. – P. 3411–3418. https://doi.org/10.3892/etm.2020.8592

31. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and metaanalysis / M. V. Holmes [et al.] // JAMA. – 2011. – Vol. 306, N 24. – P. 2704–2714. https://doi.org/10.1001/jama.2011.1880

32. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTICGENE study / J.-P. Collet [et al.] // Eur. J. Clin. Pharmacol. – 2015. – Vol. 71, N 11. – P. 1315–1324. https://doi.org/10.1007/s00228-015-1917-9

33. P2RY12 gene polymorphisms and effect of clopidogrel on platelet aggregation / E. Galić [et al.] // Coll. Antropol. – 2013. – Vol. 37, N 2. – P. 491–498.

34. Ассоциация полиморфизмов генов ITGB3, P2RY12, CYP2C19 с функциональной активностью тромбоцитов у пациентов с ишемической болезнью сердца на фоне двухкомпонентной антиагрегантной терапии / Э. Ф. Муслимова [и др.] // Тер. архив. – 2017. – Т. 89, № 5. – С. 74–78. https://doi.org/10.17116/terarkh201789574-78

35. P2Y12 receptor gene polymorphism and the risk of resistance to clopidogrel: A meta-analysis and review of the literature / G. Cui [et al.] // Adv. Clin. Exp. Med. – 2017. – Vol. 26, N 2. – P. 343–349. https://doi.org/10.17219/acem/63745

36. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene / P. Staritz [et al.] // Int. J. Cardiol. – 2009. – Vol. 133, N 3. – P. 341–245. https://doi.org/10.1016/j.ijcard.2007.12.118

37. Mean platelet volume and long-term mortality in patients undergoing percutaneous coronary intervention / B. Shah [et al.] // Am. J. Cardiol. – 2013. – Vol. 111, N 2. – P. 185–189. https://doi.org/10.1016/j.amjcard.2012.09.014

38. Increased mean platelet volume is associated with non-responsiveness to clopidogrel / E. Asher [et al.] // Thromb. Haemost. – 2014. – Vol. 112, N 1. – P. 137–141. https://doi.org/10.1160/TH13-10-0845

39. Mean platelet volume and integrin alleles correlate with levels of integrins αiibβ3 and α2β1 in acute coronary syndrome patients and normal subjects / T. J. Kunicki [et al.] // Arterioscler. Thromb. Vasc. Biol. – 2012. – Vol. 32, N 1. – P. 147–152. https://doi.org/10.1161/ATVBAHA.111.239392